hange-shashinto

07/01/2015 - "Although the incidence of grade ≧2 oral mucositis was lower for patients treated with TJ-14 compared to those treated with placebo, there was no significant difference (48.8 vs. 57.4 %; p = 0.41). "
12/01/2010 - "After the one-week topical treatment with TJ-14, thirteen of the fourteen patients (92.8 %) showed improvements in oral mucositis, with significantly decreased mean CTCAE grades (P = 0.0012). "
12/01/2010 - "The severity of oral mucositis was evaluated using the Common Terminology Criteria for Adverse Events version 4 before and after one-week TJ-14 treatment. "
12/01/2010 - "Our study aimed to determine whether TJ-14 is effective in the management of chemotherapy-induced oral mucositis. "
01/01/2020 - "The present results demonstrated the potential of TJ-14 to attenuate chemotherapy-induced stomatitis."

05/01/2003 - "Compared with the control group, the TJ-14 group showed a significant improvement in diarrhea grades ( P=0.044) as well as a reduced frequency of diarrhea grades 3 and 4 (one patient versus ten patients; P=0.018). "
05/01/2003 - "TJ-14 was effective in preventing and controlling CPT-11-induced diarrhea."
05/01/2003 - "We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced diarrhea. "
09/01/1997 - "Moreover, it was also suggested that it is possible, by the application of TJ-14, to prevent the loss of water content caused by diarrhea."
08/28/2018 - "Hangeshashin-to (Japanese herbal medicine TJ-14) is reportedly effective in preventing and controlling diarrhea associated with CPT-11. "

08/01/2020 - "Gargling with TJ-14 is a safe and effective method of administering the drug to patients with head and neck cancer."
01/01/2015 - "The present study indicates that TJ-14 is effective for ameliorating oral mucositis induced by (chemo)radiation in patients with head and neck cancers. "
01/01/2015 - "A randomized controlled trial is necessary to confirm the efficacy of TJ-14 for chemoradiation-induced mucositis in head and neck cancer patients."

11/01/2017 - "TJ-14 significantly reduced the severity of mucositis. "
11/01/2017 - "TJ-14 reduced the severity of mucositis in an animal model by suppressing the inflammatory response. "
11/01/2017 - "The percentage with severe mucositis (score ≥3) was 100% in the untreated group and 16.7% in the TJ-14 group (P < 0.05). "
01/01/2015 - "We investigated the effect of TJ-14 on mucositis, nutritional status, and the completion rate of CRT. "
01/01/2015 - "A randomized controlled trial is necessary to confirm the efficacy of TJ-14 for chemoradiation-induced mucositis in head and neck cancer patients."

01/01/2015 - "The reduction in body weight was significantly improved from 10.89 to 5.89% with TJ-14 administration (p = 0.003), and the reduction in serum albumin was also significantly decreased from 17.37 to 8.73%. "
12/01/1997 - "Repeated oral administrations of TJ-14 at 125 and 500 mg/kg significantly prevented the reduction in body weight and the onset of chronic diarrheal symptoms due to CPT-11 in a dose-dependent manner, even though it failed to show a definite effect on acute diarrheal symptoms. "
10/01/2006 - "Oral dosing (twice daily from days -1 to 4) of streptomycin 20 mg/kg and penicillin 10 mg/kg (Str/Pen), neomycin 20 mg/kg and bacitracin 10 mg/kg (Neo/Bac), both of which inhibited almost completely the fecal beta-glucuronidase activity, or TJ-14 1,000 mg/kg improved the decrease in body weight and the delayed diarrhea symptoms induced by CPT-11 (60 mg/kg i.v. from days 1 to 4) to a similar extent. "